Actually you could infer something from Novartis' response in abandoning the provisional agreement. That after a year of poring over the Covid trial data, they couldn't find even a shred of evidence of efficacy in ARDS that was worth the time, effort and money of any further research. Depsite SI's claims of "success" after some data dredging.
Actually you could infer something from Novartis' response in...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.39 |
Change
-0.075(5.12%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.37 | $9.337M | 6.672M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 80200 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 28642 | 2 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |